Author

Raidah J. Salem

Observed name: Raidah Salem

OpenAlex ID: A5018774612

Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity

2022 · Ayman Grada, James Q. Del Rosso, et al. · Frontiers in Medicine · 17

PDF

Developing a questionnaire for assessing clinician- and patient-reported outcomes in actinic keratosis: Results from an expert panel

2023 · Brian Berman, April Armstrong, et al. · JAAD International · 8

PDF

Patient-reported outcomes with sarecycline treatment for acne vulgaris: Pooled analysis of phase 3 clinical studies

2023 · Julie C. Harper, April Armstrong, et al. · Journal of the American Academy of Dermatology · 4

PDF

Trends in Oral Antibiotic Use for Acne Treatment: A Retrospective, Population-Based Study in the United States, 2014 to 2016

2023 · Ayman Grada, April Armstrong, et al. · Journal of Drugs in Dermatology · 2

43757 Improvement in pigmentation changes by Fitzpatrick skin type in actinic keratosis patients treated with tirbanibulin ointment 1%: pooled data from two Phase III studies

2023 · Andrew Blauvelt, Edward Lain, et al. · Journal of the American Academy of Dermatology · 1

PDF

Patient-Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis in Real-world Settings: PROAK Study Protocol

2022 · Brian Berman, April Armstrong, et al. · SKIN The Journal of Cutaneous Medicine · 1

PDF

76696 Achieving complete clearance (CC) in actinic keratosis (AK) after treatment with tirbanibulin 1% with mild to moderate local skin reactions (LSRs): a pooled post-hoc analysis of three Phase III studies

2026 · Edward (Ted) Lain, Naiem T. Issa, et al. · Journal of the American Academy of Dermatology

71146 Beyond the Face: Treating Truncal Acne with Sarecycline - a Multinational Phase 3 Pooled Analysis

2026 · James Q. Del Rosso, Jianzhong Zhang, et al. · Journal of the American Academy of Dermatology

76748 Efficacy of Tirbanibulin 1% Beyond Complete Clearance (CC): Percent Reduction of Actinic Keratosis (AK) Lesions as a Clinically Meaningful Endpoint

2026 · Neal Bhatia, Julia Welzel, et al. · Journal of the American Academy of Dermatology

Use of Oral Sarecycline as Monotherapy and in Combination With Topical Treatments in Patients With Acne: A Post-Hoc Analysis of Results From the Patient Reported Outcomes for Sarecycline Effectiveness and Safety (PROSES), a Single-Arm Prospective Cohort Study

2025 · Hilary Baldwin, Elizabeth Swanson, et al. · SKIN The Journal of Cutaneous Medicine

PDF

64551 Patient outcomes and satisfaction with tirbanibulin for the treatment of actinic keratosis (AK): Results from post-registration studies

2025 · Todd Schlesinger, Vishal Patel, et al. · Journal of the American Academy of Dermatology

64582 Relating patient-reported treatment satisfaction and clinical outcomes in post-registration studies of tirbanibulin for actinic keratosis (AK)

2025 · Leon Kircik, Todd Schlesinger, et al. · Journal of the American Academy of Dermatology

64484 Clearance of actinic keratosis (AK) with tirbanibulin: Comparing results from controlled trials with real-world clinical studies

2025 · Neal Bhatia, George Martin, et al. · Journal of the American Academy of Dermatology

64609 Safety and tolerability of tirbanibulin for the treatment of actinic keratosis (AK): Results from clinical trials and post-registration

2025 · Andrew Blauvelt, Mark Lebwohl, et al. · Journal of the American Academy of Dermatology

53899 Treatment success with sarecycline for treatment of acne vulgaris (AV): Comparison of results from randomized controlled trials (RCTs) and the real-world (RW) PROSES study

2024 · Emmy Graber, James Del Rosso, et al. · Journal of the American Academy of Dermatology

54040 Efficacy of tirbanibulin for the treatment of actinic keratoses (AK): Comparison of results from randomized controlled trials (RCTs) and those from the real-world (RW) PROAK study

2024 · Todd Schlesinger, Ismail Kasujee, et al. · Journal of the American Academy of Dermatology

PDF

43102 Efficacy of Sarecycline for Facial Acne Vulgaris in Patients With Skin of Color: Post Hoc Analysis of Phase 3 Trials

2023 · Jonette Keri, Julie Harper, et al. · Journal of the American Academy of Dermatology

PDF

43185 Efficacy of Sarecycline for Truncal Acne in Patients With Skin of Color: Post Hoc Analysis of Phase 3 Trials

2023 · Julie Harper, Emmy Graber, et al. · Journal of the American Academy of Dermatology

PDF

43140 Impact of Sarecycline on Quality of Life in Skin of Color Patients with Acne Vulgaris: Post Hoc Analysis of Phase 3 Trials

2023 · Andrew Alexis, Hilary Baldwin, et al. · Journal of the American Academy of Dermatology

PDF

Works count: 19

Citation count: 33

H-index: 3

I10-index: 1